A- A A+

Pharmacoepidemiologic analyses of opioid use among OEF/OIF/OND veterans.

Hudson TJ, Painter JT, Martin BC, Austen MA, Williams JS, Fortney JC, Sullivan MD, Edlund MJ.

Pain. 2017 Mar 25. doi: 10.1097/j.pain.0000000000000874.


Targeting multiple opioid receptors - improved analgesics with reduced side effects?

Günther T, Dasgupta P, Mann A, Miess E, Kliewer A, Fritzwanker S, Steinborn R, Schulz S.

Br J Pharmacol. 2017 Apr 5. doi: 10.1111/bph.13809.



By scheduling two fentanyl precursors and a fentanyl analogue, the Commission on Narcotic Drugs (CND) is sending a clear message that it can help protect people's health and respond to the urgent needs of states, the Chair of 60th Session of the CND, Ambassador Bente Angell-Hansen said today. (UNODC, USA, 16.03.2017)


Addiction Classics: Lee Robins' studies of heroin use among US Vietnam veterans.

Hall W, Weier M.

Addiction. 2017 Jan;112(1):176-180. doi: 10.1111/add.13584. Epub 2016 Sep 20. Review.


A joint US Food and Drug Administration (FDA) advisory committee has recommended that a new immediate-release (IR) opioid analgesic be approved and that labeling describe the product as deterring abuse via intranasal (IN) and intravenous (IV) routes.

The product — oxycodone hydrochloride tablets with the proposed trade name RoxyBond (Inspirion Delivery Sciences LLC) — would be indicated for the management of moderate to severe pain where use of an opioid analgesic is appropriate.

If the FDA acts on these recommendations, the product would be the first approved IR opioid with abuse-deterrent properties. (Medscape Medical News, 06.04.2017)


High Concomitant Misuse of Fentanyl in Subjects on Opioid Maintenance Treatment.

Krause D, Plörer D, Koller G, Martin G, Winter C, Adam R, Canolli M, Al-Iassin J, Musselmann R, Walcher S, Schäfer F, Pogarell O.

Subst Use Misuse. 2017 Feb 3:1-7. doi: 10.1080/10826084.2016.1246571.



EMCDDA, Lisbon, February 2017

Series type: Joint Reports


In September 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, commonly known as acryloylfentanyl, through a joint assessment. The two organisations concluded that sufficient information had been accumulated to merit the production of a Joint Report on acryloylfentanyl as stipulated by Article 5.1 of the Council Decision.


Die Zähne dieses Fisches sehen Furcht erregend aus. Leider ist er nur zehn Zentimeter lang. Dafür wirkt sein Gift ähnlich wie Heroin. (Spektrum der Wissenschaft, Bilder der Woche, 30.03.2017)


Opiate addiction has become increasingly common in Sierra Leone, where there are few avenues for drug rehabilitation. (Al Jazeera, 13.02.2017)


Intoxications involving acrylfentanyl and other novel designer fentanyls - results from the Swedish STRIDA project.

Helander A, Bäckberg M, Signell P, Beck O.

Clin Toxicol (Phila). 2017 Mar 28:1-11. doi: 10.1080/15563650.2017.1303141.



Cannabidiol: Swinging the Marijuana Pendulum From ‘Weed’ to Medication to Treat the Opioid Epidemic

Yasmin L. Hurd

Trends in Neurosciences, Publication stage: In Press Corrected Proof



Why a tiny, fanged fish produces a pain-free bite

Venom research laboratory scientists have solved the mystery of the pain-free bite from a small, fanged fish.

Researchers found that the fang blenny, a reef-dwelling fish, administers a bite that is laced with opioids. (BBC News, Science & Environment, 31.03.2017)


Anhedonia to music and mu-opioids: Evidence from the administration of naltrexone

Adiel Mallik, Mona Lisa Chanda & Daniel J. Levitin

Scientific Reports 7, Article number: 41952 (2017)



Two novel compounds powerfully suppressed animals’ pain responses, while producing little or none of the respiratory depression and liability for misuse and abuse associated with morphine and other typical opioids.

One of the compounds was extensively tested in a monkey model, laying key groundwork for moving to human trials.

The other compound was identified using computational modeling based on x-ray crystallography of a receptor’s structure, and exemplifies that technique’s potential for identifying novel compounds that can meet highly specific therapeutic needs. (NIDA Notes, 23.03.2017)


Endogenous opioids regulate moment-to-moment neuronal communication and excitability.

Winters, B. L. et al.

Nat. Commun. 8, 14611 doi: 10.1038/ncomms14611 (2017).


Tincture of opium for treating opioid dependence: a systematic review of safety and efficacy.

Nikoo, M., Nikoo, N., Anbardan, S. J., Amiri, A., Vogel, M., Choi, F., Sepehry, A. A., Bagheri Valoojerdi, A. H., Jang, K., Schütz, C., Akhondzadeh, S., and Krausz, M.

(2017) Addiction, 112: 415–429. doi: 10.1111/add.13628.



Boosting natural brain opioids may be a better way to treat disabling emotions, says new research revealing their role in regulating critical brain circuits affecting fear and anxiety.

Published in Nature Communications by University of Sydney scholars, the findings suggest medications that boost the effect of natural brain opioids might be a better way to reduce anxiety than 'receptor-binding' opioid drugs like morphine, which have major side effects. (medicalxpress.com, 23.03.2017)


Existing drug is effective in preventing withdrawal symptoms in opioid-dependent rodents

Opioid use and abuse is a significant social, health and economic issue in Canada. Researchers at the University of Calgary’s Faculty of Veterinary Medicine (UCVM) and Hotchkiss Brain Institute (HBI) at the Cumming School of Medicine (CSM) have discovered that an existing anti-gout medication is effective in reducing the severity of withdrawal symptoms in opioid-dependent rodents. Their work is leading to the development of a clinical trial at the Calgary Pain Clinic.

Neuroscientist Tuan Trang, PhD, and his team including PhD student Nicole Burma explored the underlying causes of opioid withdrawal and identified an important target in the spinal cord that is responsible for producing withdrawal symptoms in rats and mice. The target, called pannexin-1, is located throughout the body and importantly, in the brain and spinal cord. Using sophisticated biochemical, genetic and pharmacological techniques, they demonstrate how pannexin-1 on immune cells is producing withdrawal symptoms, and then prevent these symptoms using a drug that blocks pannexin-1 activity. (University of Calgary, 30.01.2017)


Abhängigkeit von verschreibungspflichtigen Opioiden - Prävention, Diagnostik und Therapie

Dependence on prescription opioids—prevention, diagnosis and treatment

Dtsch Arztebl Int 2016; 113(13): 213-20; DOI: 10.3238/arztebl.2016.0213

Just, Johannes; Mücke, Martin; Bleckwenn, Markus


Blocking microglial pannexin-1 channels alleviates morphine withdrawal in rodents.

Nicole E Burma, Robert P Bonin, Heather Leduc-Pessah, Corey Baimel, Zoe F Cairncross, Michael Mousseau, Jhenkruthi Vijaya Shankara, Patrick L Stemkowski, Dinara Baimoukhametova, Jaideep S Bains, Michael C Antle, Gerald W Zamponi, Catherine M Cahill, Stephanie L Borgland, Yves DeKoninck, Tuan Trang.

Nature Medicine, 2017; DOI: 10.1038/nm.4281



An advisory panel convened by the Food and Drug Administration to evaluate the health risks of the powerful opioid painkiller Opana ER (Oxymorphone retard, Anmerkung Forum Substitutionspraxis) says that the danger it poses as a drug of abuse outweighs its benefits as a prescription painkiller.

The time-release opioid was reformulated in 2012 to make it harder to crush. The goal was to reduce abuse by snorting it. But users quickly figured out that the new formulation could be dissolved and injected. (npr, 16.03.2017)


Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1

A H Smith, K P Jensen, J Li, Y Nunez, L A Farrer, H Hakonarson, S D Cook-Sather, H R Kranzler and J Gelernter

Molecular Psychiatry , (24 January 2017) | doi:10.1038/mp.2016.257



Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and the Anesthetic and

Analgesic Drug Products Advisory Committee (AADPAC)

Meeting March 13 -14, 2017


Yale researchers have discovered a genetic variant that may assist in personalizing treatment of opioid addiction.

The results of their genome-wide association study were published Jan. 24 in the journal Molecular Psychiatry.

The variant helped identify African Americans who might need higher doses of methadone — the most effective treatment for those dependent upon heroin or prescription painkillers. Patients receiving methadone treatment vary widely in their dose requirements. Individualized dosing is crucial to recovery: Too high of a dose can cause sedation and dangerous breathing difficulties; too low of a dose often leads to relapse. (Yale News, 24.01.2017)


Heroin use is associated with excessive histone acetylation, an epigenetic process that regulates gene expression, and more years of drug use correlate with higher levels of hyperacetylation, according to research conducted at The Icahn School of Medicine at Mount Sinai and published April 1 in the journal Biological Psychiatry. The study provides the first direct evidence of opiate-related epigenetic alterations in the human brain, indicating that the drug alters accessibility to portions of DNA to be either open or closed, thereby controlling whether genes implicated in addiction are switched on or off. (Mount Sinai Hospital, New York, Pressemitteilung, 22.03.2017)